OBI Pharma proprietary ADC technology platform “plug and play”

site-specific conjugation, scalable manufacturing process, and suitability for various antibodies, linkers, or payload, establish a straightforward and efficient process in the development of ADC Antibody Drug Conjugate (ADC) has emerged as a prominent player in the realm of anti-cancer drugs, with global pharmaceutical companies heavily investing in research and development of ADC or through acquisitions/ […]